CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 409 filers reported holding CRISPR THERAPEUTICS AG in Q3 2023. The put-call ratio across all filers is 1.08 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,532,276 | -19.1% | 33,758 | 0.0% | 0.01% | 0.0% |
| Q2 2023 | $1,895,174 | +24.1% | 33,758 | 0.0% | 0.01% | +30.0% |
| Q1 2023 | $1,526,874 | +11.3% | 33,758 | 0.0% | 0.01% | 0.0% |
| Q4 2022 | $1,372,263 | -37.8% | 33,758 | 0.0% | 0.01% | -41.2% |
| Q3 2022 | $2,206,000 | +7.6% | 33,758 | 0.0% | 0.02% | +6.2% |
| Q2 2022 | $2,051,000 | -3.2% | 33,758 | 0.0% | 0.02% | 0.0% |
| Q1 2022 | $2,119,000 | -17.2% | 33,758 | 0.0% | 0.02% | -23.8% |
| Q4 2021 | $2,558,000 | -32.3% | 33,758 | 0.0% | 0.02% | -41.7% |
| Q3 2021 | $3,779,000 | -4.8% | 33,758 | +37.7% | 0.04% | -2.7% |
| Q2 2021 | $3,970,000 | +93.0% | 24,524 | +45.3% | 0.04% | +76.2% |
| Q1 2021 | $2,057,000 | +399.3% | 16,879 | +242.7% | 0.02% | +320.0% |
| Q3 2020 | $412,000 | -46.4% | 4,925 | -88.5% | 0.01% | -50.0% |
| Q3 2017 | $768,000 | – | 42,991 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
| NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
| Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
| ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
| NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
| Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
| Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
| Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
| Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |